匹多莫德口服液治疗小儿反复呼吸道感染临床疗效观察  

Observation of clinical efficacy of pidotimod oral liquid in treatment of recurrent respiratory tract infection in children

作　　者：楚文英[1] 王俊卿[1] 

机构地区：[1]内蒙古自治区包头市第四医院儿科,内蒙古包头014030

出　　处：《中国现代医生》2014年第13期132-134,共3页China Modern Doctor

摘　　要：目的探讨匹多莫德口服液治疗小儿反复呼吸道感染的临床疗效及对免疫球蛋白的影响。方法选取2011年7月～2012年7月在我院门诊就诊的反复呼吸道感染患儿150例，将其随机分为两组：治疗组（使用匹多莫德治疗3个月）和对照组（不使用免疫调节剂）各75例。对两组患儿随访1年，统计并比较两组在随后1年中呼吸道感染发病率、各组患者的呼吸道感染治疗效果和症状消失的平均时间。结果治疗组急性期症状及体征持续时间较对照组明显缩短，治疗组呼吸道感染复发率显著降低。停止匹多莫德口服治疗3个月后免疫球蛋白在治疗组较对照组明显增高（P〈0．05）。结论匹多莫德口服液对辅助治疗小儿呼吸道感染的反复发生疗效好，安全性高，值得临床推广应用。Objective To investigate the clinical efficacy of pidotimod oral liquid and its influence on immune globulin in the treatment of children with recurrent respiratory tract infection. Methods A total of 150 children with recurrent respiratory tract infection treated in the outpatient department of our hospital from July 2011 to July 2012 were selected and randomly divided into two groups. The treatment group consisted of 75 children（receiving pidotimod treatment for 3 months） and the control group also consisted of 75 children （not receiving immunomodulatory agents）. After one-year follow-up of the two groups, the incidences of respiratory tract infection, treatment effects of respiratory tract infection and average symptom disappearance time of the two groups in this year were analyzed and compared. Results The du- ration time of symptoms and signs in the acute stage of the treatment group shortened significantly compared to that of the control group. The recurrent incidence of respiratory tract infection of the treatment group reduced significantly. Af- ter stopping pidotimod oral treatment for 3 months, the immunoglobulin of the treatment group increased significantly compared to that of the control group （P〈0.05）. Conclusion In the treatment of children with recurrent respiratory tract infection, pidotimod oral liquid shows good efficacy and high safety, thereby worthy of wide application.

关 键 词：匹多莫德口服液 反复呼吸道感染 

分 类 号：R725.6[医药卫生—儿科]